CLL/SLL

July 12, 2019July 12, 2019

Dosing Begins in Study of TP-0903, With or Without Imbruvica, for Advanced CLL and SLL

News

Dosing with the investigational therapy TP-0903 has begun in patients with previously treated chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) in an ongoing Phase 1/2 trial, its developer, Tolero Pharmaceuticals, announced. ... Read more

October 31, 2018

BeiGene Asking That Zanubrutinib Be Approved to Treat Advanced CLL/SLL Patients in China

News

Chinese regulatory authorities agreed to review a request that BeiGene’s Bruton’s tyrosine kinase (BTK) inhibitor zanubrutinib be approved to treat patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) ... Read more

April 12, 2018June 22, 2018

FDA Grants Priority Review to Duvelisib for Two Lymphoma Types

News

The U.S. Food and Drug Administration (FDA) will review an application requesting duvelisib’s full approval for the treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and accelerated approval for ... Read more